HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 72.8%

Neg 0% Neu 0% Pos 72.8%

HC Wainwright & Co. analyst Andrew S. Fein maintains Protara Therapeutics (NASDAQ:TARA) with a Buy and raises the price target from $23 to $27.